Categories
Change Password!
Reset Password!
P-CABs deliver faster symptom relief, comparable or superior healing rates, favorable safety, and potential cost benefits compared to PPIs in managing GERD and erosive esophagitis.
A comprehensive literature review of recent clinical trials suggests that potassium-competitive acid blockers (P-CABs) could offer faster and equally—if not more—effective relief than proton pump inhibitors (PPIs) for patients with gastroesophageal reflux disease (GERD) and erosive esophagitis (EE).
GERD and EE are among the most common gastrointestinal disorders globally, often requiring long-term acid suppression. While PPIs have been the cornerstone of therapy for decades, their delayed onset and occasional lack of full symptom control have prompted the search for alternatives. P-CABs represent a newer class of drugs that directly and reversibly inhibit the gastric H⁺/K⁺-ATPase enzyme, achieving rapid and potent acid suppression.
The review examined 5 randomized controlled trials investigating four P-CAB agents—vonoprazan, linaprazan glurate, fexuprazan, and tegoprazan. Across studies, P-CABs illustrated:
Notably, the analysis addresses a key gap in direct comparisons between P-CABs and PPIs, particularly in PPI-resistant GERD and EE. The authors suggest that, with growing clinical evidence, P-CABs may soon be incorporated into routine practice as either first-line agents or targeted therapies for those requiring rapid and durable relief.
Jurnal Kesehatan dan Kedokteran
Potassium-Competitive Acid Blockers (P-CABS) as a New Breakthrough in the Treatment of Gastroesophageal Reflux Disease and Erosive Esophagitis : A Recent Literature Review
Nia Ayuni Putri et al.
Comments (0)